Oncology · 2003 · 36 citations · 24 references
MedicineOncologyPharmacologyCancer Drug Toxicity ManagementChemotherapyGeriatric PharmacotherapyChemotherapy Toxicity In Older AdultsGeriatric OncologyLung CancerLung Cancer PharmacotherapyMalignant NeoplasmsToxicity ManagementGeriatric Chemotherapy ToxicityMedian AgeNon-small Cell Lung Cancer TherapyNon-small Cell Lung Cancer TreatmentPartial Response AssessmentProgressive Disease AssessmentWeekly Scheduling
OBJECTIVES: The incidence of non-small cell lung cancer (NSCLC) is increasing among the elderly. We studied the toxicity and efficacy of a weekly schedule of gemcitabine and cisplatin in elderly patients with advanced NSCLC. METHODS: Patients aged 70 years or above with advanced NSCLC were treated in a phase II prospective trial with gemcitabine 1,000 mg/m(2) and cisplatin 35 mg/m(2) on days 1, 8 and 15 every 28 days. RESULTS: Forty-eight patients with a median age of 74 years (range 70-78) participated in the study. We observed 14 cases with partial response, 14 with stable disease and 16 with progressive disease, whilst 4 patients were not evaluable. By intention-to-treat analysis, partial response rate was 31.8% whilst progressive disease was 33.3%. Median survival was 9 months; 1-year survival probability was 34.4% and median time to progression was 4 months. Grade III-IV leukopenia was observed in 5/48 patients (10.4%), 20/48 patients (41.7%) had grade III-IV thrombocytopenia and 7/48 patients (14.6%) had grade III-IV anemia. One patient experienced grade III emesis and 2 patients had grade III-IV fatigue. CONCLUSIONS: At this dose and schedule the combination of gemcitabine and cisplatin appears to be an active and well-tolerated regimen for elderly patients with advanced NSCLC.
24
Reporting results of cancer treatment
A. B. Miller, Barth Hoogstraten, M. Staquet et al. · Cancer · 1981 · 7.9K citations
Optimal two-stage designs for phase II clinical trials
Richard Simon · Controlled Clinical Trials · 1989 · 3.6K citations
Frances A. Shepherd, Janet Dancey, Rodryg Ramlau et al. · Journal of Clinical Oncology · 2000 · 2.2K citations
Medicine, Oncology, Pharmacology +16